¿Emergencia médica?¿Emergencia? Llame al 911. Salas de emergencias más cercanasEmergencias cercanas

Empresa farmacéutica (etiquetadora ante la FDA)

TaSun Pharmaceutical Industries, Inc.

Código de etiquetadora NDC: 51672

¿Qué es una etiquetadora?

La empresa cuyo nombre aparece en el envase y en el directorio de códigos nacionales de medicamentos (NDC) de la FDA. Puede fabricar el medicamento o vender uno fabricado por otra empresa. La primera parte de cada código NDC identifica a la etiquetadora.

Solo datos oficiales de la FDA

Los productos, aprobaciones y retiros vienen de la FDA (directorio NDC, Drugs@FDA, informes de retiros). Los retiros se vinculan a esta empresa por el código NDC del producto retirado.

Si tiene preguntas sobre su medicamento, hable con su médico o farmacéutico. En una emergencia, llame al 911.

De un vistazo

3Productos (NDC)

Medicamentos con receta

Solicitudes de la FDA de estos productos

  • ANDA: Solicitud abreviada (ANDA): así se aprueba una versión genérica.
AprobadaSolicitudMedicamentoPatrocinador
13 de marzo de 2003ANDA076174 Etodolac
ETODOLAC
Taro

El patrocinador es la empresa titular de la solicitud ante la FDA; puede ser distinta de la etiquetadora.

Cronología de retiros

2026

  1. 25 de septiembre de 2026 · Clase III · En curso · D-0035-2027 · Tretinoin

    Failed Impurities/Degradation Specifications

    Tretinoin Cream UPS, 0.05%, 20g, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals USA Inc., Hawthorne, NY 10532, NDC 51672-1394-0.

  2. 25 de septiembre de 2026 · Clase III · En curso · D-0033-2027 · Tretinoin

    Failed Impurities/Degradation Specifications

    Tretinoin Cream USP, 0.05%, 45g tube, Rx only, Mfd by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals USA Inc., Hawthorne, NY 10532, NDC 51672-1394-9.

  3. 31 de agosto de 2026 · Clase II · En curso · D-0848-2026 · Lidocaine

    Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).

    Lidocaine Ointment USP, 5%, Speermint Flavor, 50 g Jar, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, L6T1C, Canada, Dist By: Taro Pharmaceuticals U.S.A. Inc. Hawthorne NY 70532 NDC: 51672-3008-5

  4. 3 de agosto de 2026 · Clase II · En curso · D-0770-2026 · Carbamazepine

    CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

    Carbamazepine Tablets, USP, 200mg, 1000 count bottles, Rx only, Manufactured by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761, Distributed by: Taro Pharmaceuticals USA, Inc., Hawthorne, NY 10532, NDC 51

  5. 17 de junio de 2026 · Clase II · En curso · D-0628-2026 · Perampanel

    Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

    Perampanel CIII Tablets, 6mg, Rx only, 30 Tablets, Mfd.by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761, Dist. by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 51672-4206-6

  6. 25 de marzo de 2026 · Clase II · En curso · D-0475-2026 · Fluocinonide

    Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.

    Fluocinonide, USP, 0.05% Cream, 15g tube, Rx only, Mfd by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-1386-1

  7. 25 de marzo de 2026 · Clase II · En curso · D-0476-2026 · Fluocinonide

    Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.

    Fluocinonide, USP, 0.05% Cream, 30g tube, Rx only, Mfd by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-1386-2.

  8. 25 de marzo de 2026 · Clase II · En curso · D-0477-2026 · Fluocinonide

    Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.

    Fluocinonide, USP, 0.05% Cream, 60g tube, Rx only, Mfd by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-1386-3.

  9. 27 de enero de 2026 · Clase II · En curso · D-0342-2026 · Diclofenac

    Failed Viscosity Specifications: Out of Specification (OOS) [slightly lower than the limit] result in viscosity for Diclofenac Sodium Gel, 3%.

    Diclofenac Sodium, Topical Gel, 3%, 100 g tube, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1, Dist. by Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-1363-7

2025

  1. 30 de diciembre de 2025 · Clase III · En curso · D-0256-2026 · Fluocinolone acetonide

    Failed Impurities/Degradation Specifications: Out of specification result was obtained for the known impurity D.

    Fluocinolone Acetonide Solution Topical Solution USP, 0.01%, 60-mL bottles, Rx only, Dist. by: Taro Pharmaceuticals Inc., Hawthorn, NY 10532. NDC 51672-1365-4

Mostrar los 20 retiros anteriores

2025

  1. 26 de noviembre de 2025 · Clase III · En curso · D-0257-2026 · Clindamycin

    Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.

    Clindamycin Phosphate USP, 1% (10 mg/mL), Topical Solution, 60 mL per applicator bottle, Rx only, Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel; Dist. by: Taro Pharmaceuticals USA, Inc., Hawthorne, NY 1

2023

  1. 6 de noviembre de 2023 · Clase III · Cerrado por la FDA · D-0089-2024 · Hydrocortisone and acetic acid

    Failed Impurities/Degradation Specifications:Out-of-Specification result for Hydrocortisone related impurity and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing.

    Hydrocortisone 1% and Acetic Acid 2% Otic Solution USP, 10ml dropper bottle, RX Only, Mfd. by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada LGT 1C, Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532.

2022

  1. 25 de febrero de 2022 · Clase III · Cerrado por la FDA · D-0727-2022 · Clotrimazole and betamethasone dipropionate

    Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample

    Clotrimazole and Betamethasone Dipropionate Cream USP, 1%/0.05%,15 g tubes, Rx only, Manufactured by: Taro Pharmaceuticals Industries Ltd. Haifa Bay, Israel 2624761, Distributed by: Taro Pharmaceuticals U.S.A., Inc. Hawt

2021

  1. 15 de diciembre de 2021 · Clase I · Cerrado por la FDA · D-0375-2022 · Clobetasol propionate

    Microbial Contamination of Non-Sterile Products: presence of R. Pickettii bacteria

    Clobetasol Propionate Ointment USP, 0.05%, 60g tubes, Rx only, Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761, Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. NDC 51672-1259-3

  2. 8 de enero de 2021 · Clase II · Cerrado por la FDA · D-0246-2021 · Nortriptyline hydrochloride

    CGMP deviations.

    Nortriptyline HCl Capsules, USP equivalent to 10mg base Mfd. by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 2624761 Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532 NDC 51672-4001-1

2020

  1. 7 de febrero de 2020 · Clase I · Cerrado por la FDA · D-0863-2020 · Phenytoin

    Resuspension Problems: Two lots of Phenytoin Oral Suspension USP 125mg/5mL may coagulate and may not resuspend as per the label copy instructions.

    Phenytoin Oral Suspension USP, 125 mg/5 mL potency, 8 fl oz (237 mL) Rx Only Mfd. by: Taro Pharmaceuticals Industries Ltd. Haifa Bay, Israel 2624761 Dist. by: Taro Pharmaceuticals U.S.A. Inc. Hawthorne, NY 10532, NDC 516

2019

  1. 20 de diciembre de 2019 · Clase I · Cerrado por la FDA · D-0833-2020 · Lamotrigine

    Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate.

    Lamotrigine Tablets, USP, 100 mg, Rx Only, 100-count bottle, Mfd. by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 2624761 Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4131-1.

  2. 27 de septiembre de 2019 · Clase II · Cerrado por la FDA · D-0298-2020 · Ibuprofen

    Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

    Ibuprofen Oral Suspension USP, 100 mg/5 mL, 4 fl. oz., (118 mL), Rx only, Manufactured by: Taro Pharmaceuticals, Inc., Brampton, Ontario, Canada L6T 1C1, Distributed by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 1

  3. 27 de septiembre de 2019 · Clase II · Cerrado por la FDA · D-0299-2020 · Ibuprofen

    Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

    Ibuprofen Oral Suspension USP, 100 mg/5 mL, One Pint, (473 mL), Rx only, Manufactured by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1, Distributed by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 105

2017

  1. 21 de diciembre de 2017 · Clase III · Cerrado por la FDA · D-0249-2018 · Clobetasol propionate

    Failed Content Uniformity Specifications

    Clobetasol Propionate Cream USP, 0.05% 60 g tube, Rx only Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761 Dist. by : Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532 UPC 351672125837 NDC 516

  2. 20 de septiembre de 2017 · Clase III · Cerrado por la FDA · D-0146-2018 · Fluocinonide

    Cross contamination with other products: traces of Dapsone were found in the finished product.

    Fluocinonide Gel USP, 0.05%, 15 g tube, Rx Only, Mfd. by: Taro Pharmaceuticals Inc. Brampton Ontario Canada L6T1C1, Dist. by: Taro Pharmaceuticals U.S.A . Inc. Hawthorne NY 10532, NDC 51672-1279-1

  3. 28 de marzo de 2017 · Clase II · Cerrado por la FDA · D-0676-2017 · Nystatin and triamcinolone acetonide

    Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability

    Nystatin and Triamcinolone Acetonide Cream, USP, 100,000 USP nystatin units and 1 mg triamcinolone acetonide, distributed in a) 15 grams (NDC 51672-1263-1), b) 30 grams (NDC 51672-1263-2) and c) 60 grams (NDC 51672-1263-

  4. 17 de marzo de 2017 · Clase III · Cerrado por la FDA · D-0790-2017 · Fluocinonide

    Cross contamination with other products: Certain lots of Fluocinonide Cream were found to be contaminated with a small quantity of hydrocortisone-17-valerate.

    Fluocinonide Cream UPS, 0.05% (Emulsified Base), packaged in 60 g tube, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada, Dist. by Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-1

2016

  1. 13 de septiembre de 2016 · Clase II · Cerrado por la FDA · D-0116-2017 · Desoximetasone

    Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).

    Desoximetasone Cream USP, 0.25% 100 g, Rx only, mfd. by Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532; NDC 51672-1270-7

  2. 13 de septiembre de 2016 · Clase II · Cerrado por la FDA · D-0117-2017 · Desoximetasone

    Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).

    Desoximetasone Cream USP, 0.05% 100 g, Rx only, mfd. by Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532; NDC 51672-1271-7

2015

  1. 5 de agosto de 2015 · Clase III · Cerrado por la FDA · D-1370-2015 · Desoximetasone

    Failed Impurities/Degradation Specifications: Out of specification results for impurities testing was obtained at the 6 and 9 month time points.

    Topicort (desoximetasone) Topical Spray, 0.25%, 100 mL Bottles, Rx Only. Mfd by: Taro Pharmaceuticals, Inc., Brampton, Ontario, Canada, L6T 1C1, Dist by: TaroPharma, Hawthorne, NY 10532. NDC: 51672-5281-7.

2014

  1. 21 de octubre de 2014 · Clase III · Cerrado por la FDA · D-0049-2015 · Carbamazepine

    Marketed without an Approved NDA/ANDA: One lot was on hold-pending release status when it was erroneously made available for sale in the inventory control system. An alternate manufacturing site for the Carbamazepine API final intermediate was pending approval.

    Carbamazepine Tablets USP, 200 mg, 1000 Tablets per Bottle, Rx only, Manufactured by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 26110 Distributed by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC

  2. 25 de agosto de 2014 · Clase III · Cerrado por la FDA · D-1584-2014 · Warfarin sodium

    Failed Content Uniformity Specifications.

    Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd., Haifa Bay, Israel 26110. Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 105

2013

  1. 16 de octubre de 2013 · Clase III · Cerrado por la FDA · D-347-2014 · Ciclopirox

    Subpotent. drug

    Ciclopirox Shampoo 1%, Net Wt. 120 mL. bottles, Rx only. Mfd. by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1. Dist. by: TARO Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532. NDC 51672-1351-8.

2012

  1. 21 de noviembre de 2012 · Clase II · Cerrado por la FDA · D-086-2013 · Fluorouracil

    Product Lacks Stability: Out-of-specification (OOS) results were observed for assay and description in retain samples.

    Fluorouracil Topical Cream USP, 5%, 40 g Tube, Rx only, Mfd. by: Taro Pharmaceutical Industries, Ltd. Haifa Bay, Israel 26110, Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4118-6.

¿Qué significan las clases de retiro?

Clase I: El tipo más grave: existe una probabilidad razonable de que usar el producto cause problemas de salud graves o la muerte.
Clase II: Usar el producto puede causar problemas de salud temporales o reversibles con tratamiento, o la probabilidad de problemas graves es remota.
Clase III: No es probable que usar el producto cause problemas de salud (por ejemplo, un problema de etiquetado o de envase).

Fuentes

  1. NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  2. Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  3. Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 10 de noviembre de 2026, consultados el 14 de noviembre de 2026

Buscador de informes de retiros de la FDA → · Informar un error →